Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years
- PMID: 12886896
Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years
Abstract
Fourteen children with no detectable bactericidal antibody response to a first dose of meningococcal C conjugate vaccine at 4 years of age were given a booster dose of the same vaccine 2 years later. A rapid 1000-fold rise in postimmunization bactericidal antibody titers, a measured either 7 or 14 days later, suggested previous immunologic priming.
Similar articles
-
Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.J Infect Dis. 2001 Jan 1;183(1):97-104. doi: 10.1086/317667. Epub 2000 Nov 15. J Infect Dis. 2001. PMID: 11087205 Clinical Trial.
-
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d. Pediatr Infect Dis J. 2009. PMID: 19209097 Clinical Trial.
-
Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e69-e74. doi: 10.1093/jpids/piw094. J Pediatric Infect Dis Soc. 2017. PMID: 28339668 Free PMC article. Clinical Trial.
-
Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.Hum Vaccin Immunother. 2016 May 3;12(5):1300-10. doi: 10.1080/21645515.2015.1136040. Epub 2016 Feb 1. Hum Vaccin Immunother. 2016. PMID: 26829877 Free PMC article. Review.
-
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.Vaccine. 2009 Jun 24;27 Suppl 2:B112-6. doi: 10.1016/j.vaccine.2009.04.065. Epub 2009 May 21. Vaccine. 2009. PMID: 19464093 Review.
Cited by
-
Meningococcal vaccines.Paediatr Drugs. 2004;6(4):251-66. doi: 10.2165/00148581-200406040-00004. Paediatr Drugs. 2004. PMID: 15339202 Review.
-
Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.BMJ. 2008 Jun 28;336(7659):1487-91. doi: 10.1136/bmj.39563.545255.AE. Epub 2008 Jun 5. BMJ. 2008. PMID: 18535032 Free PMC article.
-
Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.Nat Rev Immunol. 2009 Mar;9(3):213-20. doi: 10.1038/nri2494. Nat Rev Immunol. 2009. PMID: 19214194
-
Prospects for vaccine prevention of meningococcal infection.Clin Microbiol Rev. 2006 Jan;19(1):142-64. doi: 10.1128/CMR.19.1.142-164.2006. Clin Microbiol Rev. 2006. PMID: 16418528 Free PMC article. Review.
-
Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Hum Vaccin Immunother. 2013 Dec;9(12):2505-23. doi: 10.4161/hv.26109. Epub 2013 Aug 16. Hum Vaccin Immunother. 2013. PMID: 23955057 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical